Novel compounds of the general formula: ##STR1## and the pharmaceutically acceptable acid addition salts thereof, wherein: R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently hydrogen, lower alkyl, lower alkoxy, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl or lower alkyl sulfonyl; R.sup.5 is hydrogen or lower alkyl; m is 0 or 1; W is alkylene, --CH.dbd.CH--, --O--, or --N(R.sup.6)--, where R.sup.6 is lower alkyl or hydrogen; n is 0 or 1; and Q is lower alkyl, cycloalkyl or optionally substituted phenyl. These compounds combine .beta.-blockade and calcium entry blockade properties in the same compound and therefore are useful in therapy in the treatment of cardiovascular diseases, including myocardial infarction, hypertension, arrhythmia and variant and exercise induced angina. The compounds are also useful in immunosuppressant therapy for immune diseases, such as rheumatoid arthritis.
一般式为:##STR1##及其药学上可接受的酸盐,其中:R.sup.1、R.sup.2、R.sup.3和R.sup.4各自独立地为氢、低烷基、低烷氧基、三
氟甲基、卤素、低烷基
硫基、低烷基亚砜基或低烷基磺酰基;R.sup.5为氢或低烷基;m为0或1;W为烷基、--CH.dbd.CH--、--O--或--N(R.sup.6)--,其中R.sup.6为低烷基或氢;n为0或1;Q为低烷基、环烷基或可选择取代的苯基。这些化合物在同一化合物中结合了β-阻滞和
钙通道阻滞的特性,因此在治疗心血管疾病,包括心肌梗塞、高血压、心律失常和变异性和运动诱发性心绞痛方面非常有用。这些化合物还在免疫抑制疗法中用于治疗免疫性疾病,如类风湿性关节炎。